Furthermore, lenalidomide appears to abrogate the poor prognosis of high MM PC DSG2 expression while bortezomib and possibly carfilzomib worsen prognosis, though these findings should be formally examined in the setting of controlled trials. The gene discussed is DSG2; the disease is Miyoshi myopathy.